Ginkgo nabs $DNA, biotech's most sought after ticker, for free in sweetener from NYSE
When Ginkgo went comparison shopping for a financial market to list their now $15 billion company, the New York Stock Exchange had a back-pocket sweetener the Nasdaq couldn’t offer: The most sought-after ticker in biotech, $DNA.
DNA — the most famous three letters in biology and the ticker for the world’s first biotech, Genentech, from 1999 until it was bought out by Roche for $48 billion in 2009 — will now be the ticker for Ginkgo, a 12-year-old synthetic biology startup with grand ambitions to change not only how drugs, but also everyday products like meat and perfumes, are made.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.